logo
logo

Karolinska Development’s Portfolio Company Aprea Therapeutics Secures Funding Of Usd 5.5 Million

Karolinska Development’s Portfolio Company Aprea Therapeutics Secures Funding Of Usd 5.5 Million

02/28/23, 4:39 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/SE.svgstockholm
Industry
health care
science and engineering
biotechnology
STOCKHOLM, SWEDEN, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has closed an underwritten public offering of USD 5.5 million before deducting underwriting discounts, commissions, and offering expenses.

Company Info

Company
Aprea Therapeutics
Location
stockholm, stockholms län, sweden
Additional Info
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications. For more information, please visit the company website at www.aprea.com. The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Related People